Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 11;171(9):2385–2398. doi: 10.1111/bph.12588

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Myelination is primarily mediated via HARBS and Epac. Cut myelinating cultures were treated with varying concentrations (in μM) of R-rolipram (RR; A), S-rolipram (S; B), RS25344 (RS; C),roflumilast (RF; D), Epac/PKA (ant)agonists RpcAMPS (Rp), Me-cAMP (Me), KT5720 (KT; E), and the change in myelination surrounding the lesion, normalized to control, quantified. Neurite density surrounding the lesion was restored to control levels by all drugs tested (data not shown). In addition, the extent of neurite outgrowth into the lesion is shown in F (all at 10 nM), and representative images of the lesion site are shown of untreated cut cultures (G), cultures treated with Me-cAMP (Me; H) and KT5720 (KT; I). Scale bar 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001; significant differences between control and cut, and treatments and cut.